The second test approved by the FDA, OVA1TM Ovarian Triage Test, combines a panel of five biomarkers for ovarian cancer (CA-125, transthyretin, apolipoprotein A1, ß2-microglobulin, and transferrin) identified through serum proteomics using SELDI-TOF-MS. Here, APOA1 is linked to ovarian carcinoma.